My Home About Me

by David E. Williams
Health Business Blog



Writing on the Op-Ed page of the Wall St. Journal (Oxy Morons) in the wake of OxyContin maker Purdue Frederick’s $600 million settlement for improper promotion of OxyContin, Dr. Sally Satel, psychiatrist and resident scholar at the American Enterprise Institute claims that:

[T]he real public-health damage here comes from the pitched campaign conducted by zealous prosecutors and public-interest advocates to demonize the drug itself. This is tragic because OxyContin has been a godsend for millions of patients with searing, unremitting pain from chronic back problems, rheumatoid arthritis, neurological disorders and other dire afflictions.

I agree with the second sentence but not the first. Purdue has a duty to promote the drug appropriately to keep it available for those who need it. But Purdue stepped over the line in promotion and in doing so may inadvertently make it harder for people with serious pain to get access to powerful meds. As the article points out, physicians are scared to treat pain aggressively for fear of unwanted law enforcement attention.

Purdue didn’t invent oxycodone, OxyContin’s active ingredient. Its innovation was in the slow-release formulation that allowed the longer action, which makes it so effective for constant pain. Is it too much to ask that Purdue market the product responsibly and according to its label?

Purdue’s not alone here. Cephalon (CEPH) has also aggressively promoted Actiq, a lollipop-like product meant for people with severe cancer pain, so that the vast majority of its use is off-label. Overzealous prosecutors and misguided public health advocates do exist. But pharmaceutical companies, prescribing physicians and patients also need to act responsibly.



Source: HealthBusinessBlog.com

______________________

Amateur Investors   assets   bailout   bottom   capitulation   climactic   Commodity ETFs   credit crunch   Currency ETFs   day trading   Deron Wagner   DJIA chart   Dow 1929 Crash   economic data   Emini's Nas 100   emini's S&P 500   emini's S&P 500e   ETF buy setups   ETFs (exchange traded funds)   Exchange Traded Funds (ETFs)